Evidence map›Paper›PMID 28541499›Full record

ReviewEuropean heart journal. Cardiovascular pharmacotherapy2017

Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).

Gregory Y H Lip, Antonio Coca, Thomas Kahan, Giuseppe Boriani, Antonis S Manolis, Michael Hecht Olsen, Ali Oto, Tatjana S Potpara, Jan Steffel, Francisco Marín and 5 more

Open access · bronzeAbstract readReviewConsensus Statement
In one paragraph

Review in European heart journal. Cardiovascular pharmacotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Oxidative Stress Biomarkers in Hypertension.Current medicinal chemistry · 2025
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 14 institutions in 11 countries.

Gregory Y H LipInstitute of Cardiovascular Science, University of Birmingham, UK.
Antonio CocaDepartment of Internal Medicine, Hypertension and Vascular Risk Unit, Hospital Clínic (IDIBAPS), University of Barcelona, c/Villarroel 170, 08036 Barcelona, Spain.
Thomas KahanDepartment of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
Giuseppe BorianiCardiology Department, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
Antonis S ManolisThird Department of Cardiology, Athens University School of Medicine, Athens, Greece.
Michael Hecht OlsenDepartment of Internal Medicine, Holbaek Hospital and Centre for Individualized Medicine in Arterial Diseases (CIMA), Odense University Hospital, University of Southern Denmark, Denmark.
Ali OtoDepartment of Cardiology, Memorial Ankara Hospital; Heart and Health Foundation of Turkey, Ankara, Turkey.
Tatjana S PotparaSchool of Medicine, Cardiology Clinic, Belgrade University, Clinical Centre of Serbia, Belgrade, Serbia.
Jan SteffelDepartment of Cardiology, Electrophysiology and Cardiac Devices, University Heart Center Zurich, Zurich, Switzerland.
Francisco MarínDepartment of Cardiology, Hospital Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, Murcia, Spain.
Márcio Jansen de Oliveira FigueiredoCardiology Department, Medicine School, State University of Campinas, Sao Paulo, Brazil.
Giovanni de SimoneDepartment of Translational Medical Sciences, Federico II University Hospital, via S. Pansini 5, bld # 1, Napoli 80131, Italy.
Wendy S TzouDivision of Cardiology, Cardiac Electrophysiology, University of Colorado School of Medicine, Aurora, CO, USA.
Chern En ChiangDivision of Cardiology, National Yang-Ming University, Taipei Veterans General Hospital, Taipei, Taiwan.
Bryan WilliamsInstitute of Cardiovascular Science, University College London, UK.
Aalborg University · DKDanderyds sjukhus · SEFederico II University Hospital · ITHospital Universitario Virgen de la Arrixaca · ESMemorial Ankara Hospital · TROdense University Hospital · DKPoliclinico di Modena · ITTaipei Veterans General Hospital · TWUniversidade Estadual de Campinas (UNICAMP) · BRUniversitat de Barcelona · ESUniversity College London · GBUniversity of Belgrade · RSUniversity of Colorado Denver · USZurich Heart House · CH

Funding

Medical Research Council MC_PC_13090
6 · The paper itself

Abstract

Hypertension (HTN) is a common cardiovascular risk factor leading to heart failure (HF), coronary artery disease (CAD), stroke, peripheral artery disease and chronic renal failure. Hypertensive heart disease can manifest as many types of cardiac arrhythmias, most commonly being atrial fibrillation (AF). Both supraventricular and ventricular arrhythmias may occur in HTN patients, especially in those with left ventricular hypertrophy (LVH), CAD, or HF. In addition, high doses of thiazide diuretics commonly used to treat HTN, may result in electrolyte abnormalities (e.g. hypokalaemia, hypomagnesaemia), contributing further to arrhythmias, while effective blood pressure control may prevent the development of the arrhythmias such as AF. In recognizing this close relationship between HTN and arrhythmias, the European Heart Rhythm Association (EHRA) and the European Society of Cardiology (ESC) Council on Hypertension convened a Task Force, with representation from the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE), with the remit of comprehensively reviewing the available evidence and publishing a joint consensus document on HTN and cardiac arrhythmias, and providing up-to-date consensus recommendations for use in clinical practice. The ultimate judgment on the care of a specific patient must be made by the healthcare provider and the patient in light of all individual factors presented. This is an executive summary of the full document co-published by EHRA in EP-Europace.

Indexed as

Catheter AblationAnti-Arrhythmia AgentsAntihypertensive AgentsArrhythmias, CardiacClinical Decision-MakingEvidence-Based MedicineHumansHypertensionRisk AssessmentRisk FactorsTreatment OutcomeAnti-Arrhythmia AgentsAntihypertensive AgentsArrhythmiasAtrial fibrillationHypertensionLeft ventricular hypertrophy

Identifiers

PMID28541499
PMCPMC13588646
OpenAlexW4252867012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.